Tumor News and Research

RSS

Immunotherapy accepted for coverage in MEDLINE®

Future Medicine Ltd announced today that its journal Immunotherapy (ISSN 1750-743X) has been selected for coverage in MEDLINE®. Maintained by the U.S. National Library of Medicine, MEDLINE® (Medical Literature Analysis and Retrieval System Online) is a premier bibliographic database containing approximately 13 million references to journal articles in life sciences.

19 Sep 2010

Carter blames Ted Kennedy for delay in passing health bill

A decades old grudge between former president Jimmy Carter and the late senator Edward Kennedy was renewed again Thursday when Carter criticized Kennedy's stand on the former president's health care proposal. CBS "60 Minutes" quotes Carter as saying "that Kennedy delayed comprehensive coverage for Americans for decades.

18 Sep 2010

Scott & White Healthcare recruits patients for Phase III lung cancer trial

Scott & White Healthcare in Round Rock, Texas is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease's recurrence in previously treated patients. The trial will evaluate the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).

17 Sep 2010

BCM-95 curcumin exhibits anti-inflammatory properties

Top researchers at the Gastrointestinal Cancer Research Lab at Baylor University Medical Center in Dallas are exploring the clinical applications of BCM-95®, a new patented extract of curcumin with unprecedented potency, and bioavailability.

17 Sep 2010

Myrexis to present poster on cancer metabolism inhibitor program

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the Cancer and Metabolism: Pathways to the Future meeting in Edinburgh, Scotland, as well as two additional posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics" November 16-19, 2010, in Berlin, Germany.

17 Sep 2010

Scientists discover new drug target to improve radiation effectiveness for treating cancer

Scientists at Washington University School of Medicine in St. Louis have discovered a new drug target that could improve the effectiveness of radiation for hard-to-treat cancers.

17 Sep 2010

Fat-derived stem cells can aid breast reconstruction after mastectomy

Fat-derived stem cells can be safely used to aid reconstruction of breast tissue after mastectomy as long as there is no evidence of active cancer, according to researchers at the University of Pittsburgh School of Medicine.

17 Sep 2010

Researchers discover chronic stress accelerates breast cancer progression

Chronic stress acts as a sort of fertilizer that feeds breast cancer progression, significantly accelerating the spread of disease in animal models, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.

17 Sep 2010

Researcher discover enzyme for brain tumor malignancy

Tom Wurdinger, a Dutch researcher who is connected to Harvard (Boston) and the VUmc Cancer Center in Amsterdam, has discovered the enzyme playing a very important role in the return of malign brain tumor after surgery and radiation. By making this enzyme inactive, the cancer cell can become disorganized and blow itself up.

17 Sep 2010

Devil genome sequenced: Hope for endangered Tasmanian Devils

Tasmanian Devil Salem died at age seven but made a difference to her endangered species. Only 50 micrograms of her tissue was taken and processed by Australian genetic scientist Elizabeth Murchison, using new US technology, to produce the first devil genome sequence. As a result, the fight against devil facial tumor disease now has a draft DNA reference map. This was presented at a genetic conference in Hobart yesterday.

16 Sep 2010

Professor named recipient of 2010 Phoenix Award Glass Person of the Year

Dr. Delbert Day, Curators' Professor emeritus of materials science and engineering at Missouri University of Science and Technology, has been named the 2010 Phoenix Award Glass Person of the Year, the glass industry's top honor. The Phoenix Award is given annually to a living person who has made outstanding contributions to the industry.

16 Sep 2010

Researchers develop ChIP Enrichment Analysis to identify drug targets, biomarkers

Researchers from Mount Sinai School of Medicine have developed a new computational method that will help streamline the analysis of gene expression experiments and provide scientists with a better mechanistic understanding of the differences between diseased and normal cells. The new database and software, called ChIP Enrichment Analysis (ChEA), will revolutionize how researchers identify drug targets and biomarkers.

16 Sep 2010

Phase II clinical trial shows GTx-758 reduces serum free testosterone

GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

15 Sep 2010

Stanford Cancer Center to use TrueBeam radiation therapy technology for cancer patients

On Thursday, Sept. 16, the Stanford Cancer Center will become the first treatment center on the West Coast and the fifth in the world to offer cancer patients the TrueBeam, a machine that represents an exponential leap forward in the speed, power and precision of radiation therapy.

15 Sep 2010

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

15 Sep 2010

Data from Phase II trial of zanolimumab in PTCL published in British Journal of Haematology

TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.

14 Sep 2010

Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology

Gentium S.p.A. today announced that two posters and one oral presentation on defibrotide will be presented at the 33rd World Congress of International Society of Hematology to be held at the ICC Jerusalem International Convention Center in Jerusalem, Israel, October 10-13, 2010.

14 Sep 2010

Genmab, Seattle Genetics enter ADC research collaboration agreement

Genmab A/S and Seattle Genetics, Inc. announced today that the companies have entered into an antibody-drug conjugate (ADC) research collaboration agreement.

14 Sep 2010

Platinum and light together fight cancer

Researchers continue to search for cancer treatments that effectively destroy tumor cells while protecting surrounding healthy tissue and the body. One intriguing approach involves photoactivated drugs: an inactive precursor would be administered, then the diseased tissue could be irradiated to convert the drug into its cytotoxic form locally.

14 Sep 2010

BSD publishes article on technology to improve heat therapy delivery for cancer treatment

BSD Medical Corporation today reported publication of an article on BSD's pioneering development of sophisticated technology to improve the delivery of heat therapy for the treatment of certain cancerous tumors.

14 Sep 2010